Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

February 21st 2025

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL

February 21st 2025

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

February 21st 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.

FDA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD

February 20th 2025

Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.

Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma

February 20th 2025

The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.

Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL

February 20th 2025

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC

February 20th 2025

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC

February 19th 2025

The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.

Neoadjuvant Nivolumab Plus Chemo Improves OS in Resectable NSCLC

February 19th 2025

Neoadjuvant nivolumab plus chemotherapy improved overall survival in resectable non–small cell lung cancer.

Mirdametinib Provides Long-Awaited Treatment Option in NF1-Associated PN

February 18th 2025

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

Development of Novel HER2-Targeted Therapies Could Help Reshape Treatment for HER2+ Breast Cancer

February 18th 2025

Kelly E. McCann, MD, PhD, discusses how novel ADCs and targeted therapies could improve treatment strategies in HER2-positive breast cancer.

Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL

February 17th 2025

Olalekan Oluwole, MD, MPH, discusses the incidence and resolution of CRS and neurological events beyond two weeks following axi-cel infusion in relapsed/refractory LBCL.

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response

February 17th 2025

Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.

Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management

February 17th 2025

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD

February 15th 2025

Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.

Updated Data Support Axitinib Interruption and Avelumab Maintenance After Response in Advanced RCC

February 15th 2025

Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.

Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial Cancer

February 15th 2025

Enfortumab vedotin plus pembrolizumab maintains compelling benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status

February 14th 2025

Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.

Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC for High-Risk MIUC

February 14th 2025

Consistent DFS benefit was observed with adjuvant nivolumab vs placebo in all patients with muscle-invasive bladder cancer enrolled in CheckMate-274.